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Abstract
Background—Sex-specific prediabetes estimates are not available for older-adult Americans.
Purpose—To estimate prediabetes prevalence, using nationally representative data, in civilian, 
non-institutionalized, older U.S. adults.
Methods—Data from 7,995 participants aged ≥50 years from the 1999–2010 National Health 
and Nutrition Examination Surveys were analyzed in 2013. Prediabetes was defined as 
hemoglobin A1c=5.7%–6.4% (39–47 mmol/mol [HbA1c5.7]), fasting plasma glucose of 100–125 
mg/dL (impaired fasting glucose [IFG]), or both. Crude and age-adjusted prevalences for 
prediabetes, HbA1c5.7, and IFG by sex and three age groups were calculated, with additional 
adjustment for sex, age, race/ethnicity, poverty status, education, living alone, and BMI.
Results—From 1999 to 2005 and 2006 to 2010, prediabetes increased for adults aged 50–64 
years (38.5% [95% CI=35.3, 41.8] to 45.9% [42.3, 49.5], p=0.003) and 65–74 years (41.3% [37.2, 
45.5] to 47.9% [44.5, 51.3]; p=0.016), but not significantly for adults aged ≥75 years (45.1% [95% 
CI=41.1, 49.1] to 48.9% [95% CI=45.2, 52.6]; p>0.05). Prediabetes increased significantly for 
women in the two youngest age groups, and HbA1c5.7 for both sexes (except men aged ≥75 
years), but IFG remained stable for both sexes. Men had higher prevalences than women for 
prediabetes and IFG among adults aged 50–64 years, and for IFG among adults aged ≥75 years. 
Across demographic subgroups, adjusted prevalence gains for both sexes were similar and most 
pronounced for HbA1c5.7, virtually absent for IFG, but greater for women than men for 
prediabetes.
Conclusions—Given the large, growing prediabetes prevalence and its anticipated burden, older 
adults, especially women, are likely intervention targets.
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Introduction
Prediabetes coexists with syndromes involving functional limitations,1 may lead to stroke,2 
and increases the odds of developing type 2 diabetes, which has many associated 
complications.3,4 Diabetes alone is highly prevalent worldwide and is projected to grow by 
55%, from 381.8 million in 2013 to 591.9 million in 2035.5 Older adults aged ≥60 years 
contribute about 52% to diabetes-attributable mortality worldwide, approaching 63% in 
North America and the Caribbean.5 In the U.S. alone, older adults aged ≥60 years accounted 
for 86% of all annual diabetes deaths in 2007.6 Diabetes complications afflict older-adult 
Americans and include diabetic retinopathy8 and hospitalizations for conditions like 
nontraumatic lower-extremity amputation,9 end-stage renal disease,10 and diabetic 
ketoacidosis.11 Diabetes complications often increase with age. For example, in 2010, for 
diabetic patients aged 64–74 years and ≥75 years, respectively, the numbers (and 
percentages) of all hospital discharges for diseases of the circulatory system as first-listed 
diagnoses were 322,000 (25.8%) and 463,000 (30.3%).12,13 Similar increases exist for 
hospitalizations for lower-extremity conditions4 and self-reported mobility limitation.15 The 
associated costs of medical care for older adults with diabetes are immense. In 2012 in the 
U.S., $104 billion, or roughly 59%, of the $176 billion spent on total direct healthcare costs 
was among diabetic adults aged ≥65 years.16 Importantly, 57%, or ≥$59 billion, went to 
institutional care-primarily nursing homes, where women account for 66% of all costs, and 
also hospice care.16
For these reasons, knowing the prevalence of prediabetes is important. In 2012, an estimated 
86 million Americans were at high risk for diabetes assessed by fasting plasma glucose 
(FPG) or hemoglobin A1c (HbA1c) tests.17 Bullard and colleagues18 recently estimated that, 
during 2007–2010, about 48% of U.S. adults aged ≥65 years had prediabetes. These authors 
did not offer estimates by sex, greater age disaggregation, or demographic characteristics, 
which frequently are included for diabetes-related indicators in national surveillance 
systems.7 Having refined prediabetes estimates should assist programs, such as the U.S. 
National Diabetes Prevention Program, which will likely target this rapidly growing age 
group.19 Offering prediabetes estimates according to socioeconomic and social 
circumstances may potentiate a more effective physician—patient encounter.20,21 
Partitioning prediabetes data by age and sex may help illuminate the noted growth in 
prediabetes among those with normal BMI.18 As such, prediabetes data were analyzed using 
the National Health and Nutrition Examination Survey (NHANES) for older adults aged 50–
64 years, 65–74 years, and ≥75 years, with the first group serving to anticipate the growth of 
the older-adult population as they reach age 65 years.
Methods
Data Source and Population
Methods were previously explained in detail for a similar analysis of prediabetes using the 
1999–2010 NHANES for participants aged ≥12 years.18 The NHANES are repeated, cross-
sectional surveys representative of the civilian, noninstitutionalized U.S. population, 
conducted by the National Center for Health Statistics (NCHS),22–24 which uses a stratified, 
multistage design and independent, 2-year survey cycles. Response rates were similar across 
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six cycles from 1999 through 2010, ranging from 75% to 80%.22 The NCHS IRB approved 
the survey protocol.
After completing a household interview, NHANES participants undertook a physical 
examination and other interviews at a mobile examination center. The final analytic sample 
included 7,995 participants (3,951 men and 4,044 nonpregnant women) from the morning 
mobile examination center session who had fasted 8–23.9 hours, had complete data for 
HbA1c and FPG, and offered self-report of diagnosed diabetes.
Measures
HbA1c assays were completed with high-performance liquid chromatography using certified 
instruments22 and incorporating the reference method used for the Diabetes Control and 
Complications Trial. During 1999–2010, three modifications influenced NHANES HbA1c 
measurement methods: two instrument changes, a laboratory site change, and a high-
performance liquid chromatography method change described elsewhere.18 NCHS 
recommended no corrections for HbA1c data.26
A hexokinase enzymatic method27,28 was used for FPG measurements having two 
instrument changes. To ensure comparability to earlier years, NCHS recommended using 
Deming regression equations27,28 as follows: 1999–2004 (FPG × 0.9835) and 2005–2010 
(0.9835 × FPG − 1.139).
Data were aggregated to produce reliable estimates for two 6-year periods (1999–2004 and 
2005–2010). Prediabetes was defined as havingHbA1c=5.7%–6.4% (39–47.9 mmol/mol 
[HbA1c5.7]), FPG of 100.0–125.9 mg/dL (impaired fasting glucose [IFG]), or both. 
Participants with values of HbA1c or FPG beyond these respective upper limits, or those 
with self-reported diagnosed diabetes, were classified as having diabetes (n=3,197; 2,764 
diagnosed, 433 undiagnosed). Standardized weight and height measurements yielded three 
BMI (weight [kg]/height [m]2) categories of normal (and under-) weight (<25.0), 
overweight (25.0–29.9), and obese (≥30). Standard data for age (years), sex, race/ethnicity 
(non-Hispanic white, non-Hispanic black, Mexican American, other race/ethnicity), poverty-
to-income ratio (PIR; <1.0, 1–2.9, ≥3.0), education (less than high school, high school 
graduate, some college or higher), and living alone (no/yes) were used. All variables were 
used previously,18 except living alone, which may increase the risk of diabetes.29
Statistical Analysis
All analyses were conducted in 2013. As previously done,18 missing data for PIR (n=755), 
BMI (n=254), and education (n=20) were imputed using the PROC MI procedure in SAS, 
version 9.2. All dependent, independent, and design variables were included in each 
imputation model.
Participants with diabetes were included in the denominator to estimate prevalences of 
prediabetes, HbA1c5.7, and IFG for 1999–2004 and 2005–2010.
For comparison to prior work,18 computed age-adjusted estimates using the direct method 
were standardized to the 2000 U.S. Census population based on three age groups: 50–64 
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years, 65–74 years, and ≥75 years. Age-adjusted prevalences for the two periods were 
compared with a t-test. Multivariable logistic regression was used to calculate and evaluate 
adjusted prevalences (predictive margins), independent of major risk factors for prediabetes, 
by controlling for age, sex, race/ethnicity, PIR, education, living alone, BMI, and survey 
period for the U.S. population aged ≥50 years, those aged ≥65 years, and for selected 
subgroups.
First-order interactions of survey period with each sociodemographic variable and BMI were 
tested using Satterthwaite-adjusted F statistics.30 A dichotomous variable represented each 
period (eg., 1=1999–2004, 2=2005–2010). Appropriate sampling weights were used by 
ensuring that their summation was equivalent to the total U.S. popuation,31 to account for 
the NHANES complex sampling design and nonresponse Multiple comparisons were not 
accounted for owing to the descriptive nature of the study.32 Values of p < 0.05 were 
considered statistically significant; however, given the large number of comparisons and the 
descriptive nature of the study, the significance should be interpreted together with the 
magnitude of the difference.
All analyses were performed using SAS-callable SUDAAN, version 10.0.1.
Results
For both men and women aged ≥50 years, there were no significant changes in the 
distributions of age, racial/ethnic, and income groups (Table 1). The proportion of men 
living alone, however, increased significantly by 4.3 percentage points (ppts; p<0.01). 
Among women, the BMI distribution changed significantly (p<0.05); however, only the 
proportion classified as being obese increased significantly by 5.0 ppts (p=0.012).
During the 12-year span, the proportions of older adults with normal glycemic status 
decreased significantly for those aged 50–64 years, 65–74 years, and ≥75 years, respectively 
by: −8.4 ppts (from 45.7% [95% CI=42.1, 49.4] to 37.3% [95% CI=34.5, 40.3]), −8.5 ppts 
(from 32.6% [95% CI=28.7, 36.9] to 24.1% [95% CI=20.8, 27.8]), and −8.8 ppts (from 
33.6% [95% CI=29.6, 37.8] to 24.8% [95% CI=21.8, 28.2]) (p< 0.001 for each comparison, 
data not shown). Focusing only on 2005–2010 proportions, normoglycemia decreased 
significantly as age increased from 50–64 years to 65–74 years (13.2 ppts; p< 0.001) and to 
age ≥75 years (12.5 ppts; p< 0.001). However, there was no significant change in 
normoglycemia between those aged 65–74 years and ≥75 years (p>0.05).
Table 2 provides prevalences for diagnosed and undiagnosed diabetes and prediabetes, 
which, when totaled, reflect all dysglycemia. By 2005–2010, dysglycemia prevalence 
ranged from 55.6% for women aged 50–64 years to 78.1% for men aged ≥75 years. Notably, 
there was a sex disparity in dysglycemia that decreased with age from 14.9 ppts for ages 50–
64 years (70.4% vs 55.6% for men and women, respectively) to roughly 5 ppts for ages 65–
74 years (77.9% vs 74.2%), and ≥75 years (78.1% vs 73.2%).
For adults aged ≥50 years, the age-adjusted prevalence of prediabetes increased significantly 
over time by 6.4 ppts from 40.6% (95% CI=37.8, 42.9; crude: 40.3% [95% CI=37.8, 42.9]) 
to 47.0% (95% CI=45.0, 49.1; crude: 46.9% [95% CI=44.7, 49.1] (p< 0.001). By sex, the 
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age-adjusted prevalences of prediabetes for men did not change significantly from 46.5% 
(95% CI= 43.1, 50.0; crude: 46.3% [95% CI=42.7, 50.0]) to 50.1% (95% CI=46.9, 53.2; 
crude: 50.5% [95% CI=46.9, 53.4]). However, for women, the age-adjusted prevalence 
increased significantly by 8.7 ppts from 35.6% (95% CI=32.8, 38.5; crude: 35.3% [95% 
CI=32.5, 38.2]) to 44.3% (95% CI=41.6, 47.0; crude: 44.1% [95% CI=41.4, 46.9]) 
(p<0.001).
Age-specific prevalences of prediabetes for men and women combined increased 
significantly as follows for adults aged: 50–64 years, by 7.4 ppts (from 38.5% [95% 
CI=35.3, 41.8] to 45.9% [95% CI=42.3, 49.5]; p=0.003); 65–74 years, by 6.6 ppts (from 
41.3% [95% CI=37.2, 45.5] to 47.9% [95% CI=44.5, 51.3]; p=0.016); but not for ≥75 years 
(from 45.1% [95% CI=41.1,49.1] to 48.9% [95% CI=45.2, 52.6]; p>0.05).
Table 3 presents sex-specific changes in multivariate-adjusted prevalences of prediabetes 
status. For adults aged 65–74 years and ≥75 years, there were no significant changes in 
prevalence for prediabetes or for IFG, except for women aged 65–74 years, among whom 
prediabetes increased 9.5 ppts, from 38.5% to 48% (p=0.014). The absence of significant 
increases for prediabetes occurred despite significant increases in HbA1c5.7. Specifically, 
HbA1c5.7 increased significantly (p<0.05) for all sex–age groups, except men aged ≥75 
years, and were large (e.g., roughly 10–15 ppts) in magnitude.
For the five other characteristics in Table 3, prediabetes prevalence among men remained 
stable over time. However, women manifested significant increases for non-Hispanic white 
(p=0.004); the middle PIR group (p=0.044); less than high school education (p< 0.001) and 
some college or higher (p<0.05); living alone (p=0.009); and those having normal weight 
(p=0.005). Conversely, for IFG, non-Hispanic black women showed decreased prevalence 
(p=0.03), with no other significant changes for women or men across all other 
characteristics. Men showed significant increases in HbA1c5.7 for non-Hispanic white 
(p=0.012); the highest PIR group (p< 0.001); those with some college education or higher 
(p=0.04); both living-alone categories (p=0.03 for each); and those who were overweight 
(p=0.04). Women manifested increases for the same characteristics as men, but additionally 
for the lowest PIR group (p=0.003); the middle PIR group (p=0.002); those with less than 
high school education (p=0.03); and those of normal weight (p< 0.001).
Among adults aged 50–64 years, prediabetes prevalence was significantly greater among 
men than women by 15.3 ppts (46.6% vs 31.3%; p=0.04) in the first time period and 10.2 
ppts (p=0.003) in the second time period (Table 2). A similar pattern was found for IFG for 
adults aged 50–64 years (p<0.001 for each), ≥75 years (p=0.028 for 1999–2004, and 
p=0.003 for 2005–2010). Table 3 provides the multivariate-adjusted prevalence of IFG in 
the first time period, which was higher for men than for women: at age ≥75 years (p=0.041); 
among non-Hispanic whites (6.8 ppts, p=0.04); the highest PIR group (p=0.02); in those 
with less than high school education (9.8 ppts, p=0.048); and in those with normal weight 
(p=0.01). Except for those with less than high school education, these significant sex 
differences persisted into the second time period and also included the middle PIR group 
(p=0.03) and overweight group (p=0.02).
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Sex differences in crude prevalence were not found for HbA1c5.7 (Table 2). After 
multivariate adjustment (Table 3), for only the second time period, women had a 
significantly higher prevalence of HbA1c5.7 than men among those aged ≥75 years (6.6 
ppts; p=0.03); the lowest- (20.7 ppts; p<0.001) and middle PIR groups (8.8 ppts, p<0.05); 
those with some college or higher education (12.8 ppts, p<0.001); those not living alone (8.2 
ppts, p=0.012); and those who were overweight (10.7 ppts, p=0.04).
IFG yielded significantly higher multivariable-adjusted prevalence among non-Hispanic 
whites than non-Hispanic blacks of either sex (Table 3). In both time periods, estimates for 
non-Hispanic white men were significantly higher than for non-Hispanic black men, 16.4 
ppts (p<0.003) and 18.2 ppts (p<0.001), respectively. Comparable racial/ethnic differences 
for women were 10.2 ppts (p=0.02) and 18.3 ppts (p<0.001), respectively. The differences 
between non-Hispanic whites and Mexican-Americans were only significant among men in 
the first time period (9 ppts, p=0.04). HbA1c5.7 prevalence was significantly higher among 
non-Hispanic black men than non-Hispanic white men in the first time period (9.7 ppts, 
p=0.04), with no other racial/ethnic differences. In light of these changes, prediabetes 
prevalence was significantly higher in the second time period among non-Hispanic white 
than non-Hispanic black adults (for men, 15.8 ppts, p=0.002; for women, 11.8 ppts, p=0.02) 
or Mexican American women (11.8 ppts, p=0.02).
Discussion
Older adults in the U.S. contribute significantly to the growing diabetes burden. Normal 
glycemia was found to decrease over time, whereas dysglycemia (e.g., all diabetes and 
prediabetes) afflicted almost three in four older adults aged ≥65 years by 2005–2010. 
Almost 50% of men and 40% of women aged 50–64 years (i.e., most baby boomers) were 
identified as having prediabetes (Appendix Figure 1, available online), and by 2030 they 
will all be aged ≥65 years. For this increasingly large segment of the U.S. population,33 
complications may result from prediabetes itself or its progression to diabetes, resulting in 
reduced function and well-being. These outcomes are particularly important to women in the 
context of institutional care. For example, despite nearly equal numbers of diabetic men and 
women in the U.S.,16 among nursing home residents with diabetes in 2004, women 
outnumbered men by almost 2.9-fold (60,200 vs 20,800, respectively).34
Fortunately, a major U.S. clinical trial revealed the potential to prevent or delay the 
progression to diabetes among high-risk adults.35 In that trial, adults aged ≥60 years 
experienced a 71% reduction in risk of developing diabetes via intensive lifestyle 
intervention, but no reduction with metformin. Over a 10-year follow-up, older adults 
maintained a high percentage of initial weight loss (e.g., 6.6% or 4 kg).36 As such, lifestyle 
intervention may be the only way to prevent or delay diabetes in this age group, among 
whom efficacy was apparently higher than their younger counterparts.35,36 Cost 
effectiveness analyses have even suggested that lowering the Medicare eligibility age from 
65 to 60 years could produce considerable economic benefit.37 Providing prediabetes 
estimates by sociodemographic characteristics should help to tailor effective interventions to 
the specific needs of older adults, including those with physical function limitations and 
comorbid conditions1 as was examined among those with diabetes.38
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There was a marked discordance between prediabetes estimates based on FPG or HbA1c 
alone, or as compared to prediabetes overall. This discordance also existed between the 
sexes, which is consistent with reports from populations of the U.S.,3,39 Sub-Saharan 
Africa,40 and Korea.41 The plausible biological mechanism for this sex difference seems to 
be less related to anthropometric differences, and more related to differences in insulin 
sensitivity and beta cell function.42 Given the current and projected preponderance of older 
women in the U.S., the common use of FPG may likely undercount the numbers of older 
women at high risk of prediabetes and its complications.
When using 6-year time periods, it was found that the previously noted increasing 
prediabetes prevalence of 8.8% among Americans aged ≥12 years with normal BMI18 was 
manifested only among women aged ≥50 years for prediabetes (10.2 ppts), and especially 
for HbA1c5.7 (13.8 ppts) (Appendix Table 1, available online). Women had even greater 
increases when partitioned into age ≥65 years, reaching 12 ppts for prediabetes, and almost 
17 ppts for HbA1c5.7. Bullard et al.18 did not identify reasons for this increase in the 
general U.S. population. For older adults, it may be that sarcopenia plays a role. For 
example, using 1988–1994 NHANES III data, Srikanthan and colleagues43 found that adult 
men and women aged ≥60 years with sarcopenia but no obesity, compared to their peers 
having neither condition, had significantly higher odds of having insulin resistance or 
prediabetes (IFG or HbA1c=6.0%–6.4%) by 34% and 50%, respectively. Sarcopenia 
without obesity was not associated with HbA1c alone, perhaps due to more restrictive 
HbA1c cutoff points.43 Although not pertaining exclusively to normal-weight women, this 
provides a limited explanation for the association found for the overall prediabetes estimate. 
Future research efforts might seek to better explain the large increase in prediabetes 
prevalence among the oldest women in the U.S. population.
A major strength of the study was the use of nationally representative samples of the U.S. 
noninstitutionalized population. Standardized protocols enhanced comparability across 
NHANES survey cycles and consistent prediabetes criteria were used, despite changing 
definitions for prediabetes since 2003.44,45 There were, however, some limitations. First, 
using single laboratory measurements of HbA1c and FPG may have misclassified 
prediabetes owing to intra-individual variability. Second, NHANES sampling changes from 
2003 to 2010 could have induced nonrandom error, thereby potentially affecting HbA1c or 
FPG values, and prediabetes prevalence patterns. Third, changes in measurement methods of 
HbA1c and FPG because the 2003–2004 NHANES cycle26–28 might have influenced data 
quality, although NCHS deemed these measures suitable for analysis.26 Aggregating 6 years 
of data and using HbA1c and FPG measures to assess prediabetes not only stabilized 
estimates but also attenuated the effect of these potential limitations. Finally, using cross-
sectional surveys eliminated the ability to fully assess transitions between different glycemic 
states. Future prospective cohort studies will better characterize glycemic transitions.
Ideally, population-level interventions to prevent or reduce the rightward shift in the 
distribution of glucose across the life stages, notably in young adulthood and mid-life, 
should be the goal, given the profound implications for a subsequent late-life societal burden 
in lost productivity and institutional care. However, the very large and growing prevalence 
of prediabetes in older-adult Americans, among whom associated burdens are more likely to 
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be imminent and most profound, especially for women, makes them a target group that 
could be of paramount importance for interventions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Appendix: Supplementary Data
Supplementary data associated with this article can be found at http://dx.doi.org/10.1016/
j.amepre.2014.10.004.
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Table 1
Characteristics of U.S. Adults Aged ≥50 Years, by Sex and Survey Period, NHANES 1999–2010
Characteristic
Men Women
Prevalence (95% CI) by survey periods Prevalence (95% CI) by survey periods
1999–2004 2005–2010 1999–2004 2005–2010
n 1,806 2,145 1,873 2,171
Population size (millions) 35.7 41.2 42.8 48.3
Age group (years), %
 50–64 60.3 (57.0, 63.5) 60.7 (58.0, 63.3) 56.8 (54.3, 59.4) 56.3 (52.9, 59.7)
 65–74 24.3 (22.1, 26.8) 23.3 (20.9, 25.9) 22.8 (20.1, 25.7) 23.6 (21.1, 26.2)
 ≥75 15.3 (13.6, 17.2) 16.0 (14.5, 17.6) 20.4 (18.2, 22.7) 20.1 (17.5, 23.0)
Race/ethnicity, %a
 Non-Hispanic white 81.2 (76.6, 85.1) 78.1 (74.1, 81.6) 79.4 (75.1, 83.1) 77.6 (73.6, 81.2)
 Non-Hispanic black 7.6 (6.0, 9.4) 9.5 (7.6, 11.8) 9.0 (6.9, 11.8) 10.0 (7.9, 12.6)
 Mexican American 3.8 (2.6, 5.4) 4.7 (3.3, 6.8) 3.5 (2.2, 5.5) 4.6 (3.3, 6.5)
 Other 7.4 (4.9, 11.1) 7.7 (5.9, 10.2) 8.1 (5.5, 11.7) 7.7 (6.0, 10.0)
PIR group, %
 <1.0 8.0 (6.4, 10.0) 7.9 (6.6, 9.5) 11.6 (9.4, 14.3) 10.1 (8.6, 11.8)
 1–2.9 33.6 (30.0, 37.4) 34.7 (31.5, 38.1) 41.0 (37.8, 44.4) 40.1 (36.8, 43.5)
 ≥3.0 58.4 (54.6, 62.2) 57.3 (53.6, 61.0) 47.3 (43.8, 50.9) 49.9 (46.0, 53.7)
Education, %
 <High school 23.8 (21.3, 26.6) 20.4 (17.8, 23.2) 25.4 (22.6, 28.3) 20.2 (17.8, 22.9)
 High school graduate 22.4 (19.5, 25.7) 23.1 (20.1, 26.6) 27.8 (25.3, 30.5) 28.9 (26.3, 31.6)
 Some college or higher 53.8 (49.2, 58.2) 56.5 (51.8, 61.1) 46.8 (43.5, 50.1) 50.9 (47.6, 54.3)
Living alone, %b
 No 88.0 (85.9, 89.8)* 83.7 (81.9, 85.5)* 74.4 (71.7, 77.0) 75.8 (73.1, 78.2)
 Yes 12.0 (10.2, 14.1)* 16.3 (14.5, 18.1)* 25.6 (23.0, 28.3) 24.2 (21.8, 26.9)
BMI group (kg/m2), %
 Normal (<25.0) 25.9 (23.6, 28.4) 24.0 (21.5, 26.6) 33.9 (30.4, 37.6)** 30.5 (27.8, 33.3)**
 Overweight (25.0–29.9) 42.5 (39.0, 46.0) 39.4 (37.0, 41.8) 32.1 (29.0, 35.4)** 30.5 (27.9, 33.3)**
 Obese (≥30.0) 31.6 (29.0, 34.3) 36.7 (33.4, 40.0) 34.0 (31.0, 37.1)** 39.0 (36.6, 41.4)**
Note: Data presented are weighted percentages unless otherwise noted. Boldface indicates statistical significance (*p=0.003; **p=0.044).
a
Individuals for other racial/ethnic groups are included in the denominator but their separate estimates are not presented.
b
p-values for equal proportions were calculated from an F-test.
NHANES, National Health and Nutrition Examination Survey; PIR, poverty-income ratio.
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